Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Treasury Shares (2016 - 2025)

Historic Treasury Shares for Anika Therapeutics (ANIK) over the last 16 years, with Q2 2025 value amounting to $957338.0.

  • Anika Therapeutics' Treasury Shares rose 170629.81% to $957338.0 in Q2 2025 from the same period last year, while for Jun 2025 it was $957338.0, marking a year-over-year increase of 170629.81%. This contributed to the annual value of $836562.0 for FY2024, which is 845.31% up from last year.
  • Per Anika Therapeutics' latest filing, its Treasury Shares stood at $957338.0 for Q2 2025, which was up 170629.81% from $241000.0 recorded in Q1 2025.
  • In the past 5 years, Anika Therapeutics' Treasury Shares ranged from a high of $957338.0 in Q2 2025 and a low of $53000.0 during Q2 2024
  • For the 5-year period, Anika Therapeutics' Treasury Shares averaged around $581957.5, with its median value being $702851.5 (2022).
  • Its Treasury Shares has fluctuated over the past 5 years, first plummeted by 8036.59% in 2024, then soared by 170629.81% in 2025.
  • Over the past 5 years, Anika Therapeutics' Treasury Shares (Quarter) stood at $412658.0 in 2021, then soared by 63.67% to $675405.0 in 2022, then grew by 14.21% to $771358.0 in 2023, then grew by 8.45% to $836562.0 in 2024, then increased by 14.44% to $957338.0 in 2025.
  • Its last three reported values are $957338.0 in Q2 2025, $241000.0 for Q1 2025, and $836562.0 during Q4 2024.